[Use of pentoxifylline in diabetes with intermittent claudication].
The authors have investigated the effect of pentoxifylline administration (400 mg in three doses) in diabetic subjects with lower limb vasculopathy. The results have shown a marked improvement in clinical symptoms and VRBC and a slight improvement in fibrinogen and blood lipid levels.
D002784:Cholesterol / Q000097:blood; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D004912:Erythrocytes / Q000502:physiology; D005340:Fibrinogen / Q000032:analysis; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D010431:Pentoxifylline / Q000627:therapeutic use*; D013805:Theobromine / Q000031:analogs & derivatives*; D014462:Ultrafiltration
D002784:Cholesterol; D005340:Fibrinogen; D006442:Glycated Hemoglobin; D008055:Lipids; D010431:Pentoxifylline; D013805:Theobromine
L'uso della pentossifillina nei diabetici con claudicatio intermittens.